Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

CymaBay Therapeutics logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

Advanced Chart

Key Stats

Today's Range
$32.48
$32.48
50-Day Range
$32.18
$32.48
52-Week Range
$7.26
$32.50
Volume
73 shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CBAY Stock News Headlines

This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.tc pixel
Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
CBAY Jul 2024 34.000 call
CBAY Apr 2024 31.000 put
CBAY Oct 2024 33.000 call
See More Headlines

CBAY Stock Analysis - Frequently Asked Questions

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.42 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that CymaBay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
2/28/2024
Today
8/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CBAY
CIK
1042074
Employees
101
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.37 million
Net Margins
N/A
Pretax Margin
-339.11%
Return on Equity
-50.72%
Return on Assets
-31.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.96
Quick Ratio
10.96

Sales & Book Value

Annual Sales
$31.07 million
Price / Sales
119.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.58 per share
Price / Book
12.59

Miscellaneous

Outstanding Shares
114,724,000
Free Float
106,693,000
Market Cap
$3.73 billion
Optionable
Optionable
Beta
0.32

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CBAY) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners